Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XILLIX FDA APPROVED -- Ignore unavailable to you. Want to Upgrade?

To: jeffrey P. Sponseller who wrote (291)	8/24/1998 11:50:00 PM
From: Jason Marcotte	Respond to of 572

My guess is because of the flight to quality. Speculative excesses are being wrung out of this market, and let's face it, XLX has yet to show a profit yet. I still think it is a great buy - in moderation. Jason

To: jeffrey P. Sponseller who wrote (291)	8/24/1998 11:54:00 PM
From: Jason Marcotte	Respond to of 572

Subject: Hot Off The Wire: XILLIX TECHNOLOGIES CORP. Date: Mon, 24 Aug 1998 13:32:28 -0400 From: cthompson@cdn-news.com To: cthompson@cdn-news.com =================================================================== Canadian Corporate News --- Hot Off The Wire News Release for XILLIX TECHNOLOGIES CORP. =================================================================== ------------------------------------------------------------------- E*TRADE Canada introduces another exclusive! Pay NO COMMISSIONS on over 600 mutual funds For more information visit us at: www2.cdn-news.com ------------------------------------------------------------------- NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS FOR: XILLIX TECHNOLOGIES CORP. TSE SYMBOL: XLX AUGUST 24, 1998 Xillix Technologies Issues Statement RICHMOND, BRITISH COLUMBIA--At the request of the Toronto Stock Exchange, Xillix Technologies Corp. released the following statement: "The Company does not have any pending announcements, not is it aware of any developments or issues with respect to its operations, products of ownership structure, which would explain the current downward movement in the price of its common shares." Sales of the Xillix LIFE-Lung Fluorescence Endoscopy System (TM), by Olympus Optical Co. Ltd., continue to meet the Company's sales projections; clinical testing of the Xillix LIFE-GI Fluorescence Endoscopy System (TM), for the early detection of gastrointestinal cancer, are currently underway; and the Company is exploring new applications for its patented fluorescence endoscopy system in the area of cervical, bladder, head and neck cancers. Xillix Technologies Corp. is a leader in the development and commercialization of proprietary medical imaging technology which helps physicians diagnose early-stage cancer. When tissue containing abnormal cells is exposed to light from Xillix's fluorescence imaging devices, physicians are able to detect precancerous and cancerous cells. The Company's lead product, called the Xillix LIFE-Lung Fluorescence Endoscopy System has been approved for sale in the United States, Canada, Europe and Japan. Worldwide marketing has been granted to Olympus Optical Co. Ltd., of Tokyo, the international endoscopy market leader. Xillix has also formed a strategic alliance with Miravant Medical Technologies of Santa Barbara, California, to co-develop medical devices for early cancer detection, localization and treatment. -30- FOR FURTHER INFORMATION PLEASE CONTACT: Xillix Technologies Corp. Laurie McMichael Manager, Investor Relations and Corporate Communications (604) 278-5000 (604) 278-3356 (FAX) website: www.xillix.com

To: jeffrey P. Sponseller who wrote (291)	8/24/1998 11:59:00 PM
From: Garry K.	Read Replies (2) \| Respond to of 572

Jeffrey: Margin calls, jittery investors.....that's what it appears to me IMHO. Volume has been low the past couple of weeks, with 100k trading today over 65 trades which indicates that some small investors are cashing in their chips. I have posed the question to IR on a couple of occasions on identifying possible competitors in the endoscopy field, and I was told there is none. With Olympus having 70% of this market, and with their dedication to Xillix's science, I would say this is a good indication that this true. I never thought I would see Xillix at these levels where I first began purchasing them about 3 years ago. Fundamentally in my opinion, the company is in a much stronger position now than it ever was back in 1995. That's why I am more than happy to assist those who want to unload their shares at $1.20. Value investing is about purchasing quality businesses, patiently acquired. The patience is the hard part. Good luck! Garry